The presence of LOCM such as Uttravist in the blood stream encourages lowering of blood\viscosity v ia osmodilution. LOCM passes in to glomerular filtrate. Residual hyperosmolality of filtrate increases osmotic pressure of tubular fluid and reduces water reabsorption. More water is retained in tubules, d iluting and further lowering viscosity of tubular fluid (osmodiuresis-). Preserved GFR and fluid flow through tubules and renal blood vessels.
Key Traits
Preclinical evidence
Unlike IOCM, LOCM such as Ultravist encourages dilution of blood and urine, lowering in vivo viscosity and preserving renal hemodynamics.
Clinical evidence
Osmodilution and osmodiuresis has seen in patients receiving Ultravist': Marked (~20%) decrease in blood viscosity measure in 10 patients undergoingDSA with Ultravist' 370.
Clinical data
In humans undergoing cardiac intervention, compared to IOCM iodixanol, LOCM Ultravist
![]() |
REGE IMAGING & CINE FILMS (P) LTD.
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |